Causes of death and posttransplant toxicities by era
| . | All patients (N = 342) . | AHCT in 2001-2010 (N = 159) . | AHCT in 2011-2020 (N = 183) . |
|---|---|---|---|
| All-cause mortality | |||
| Total number of deaths | 74 | 55 | 19 |
| Median follow-up after AHCT | 5.9 y | 11.6 y | 4.0 y |
| 4-y OS estimate | 83.8% | 79.0% | 89.1% |
| Causes of death | |||
| PD, N (%)∗ | 33 (45%) | 23 (42%) | 10 (53%) |
| Infection/sepsis | 10 (14%) | 8 (15%) | 2 (11%) |
| Cardiovascular disease | 7 (9%) | 5 (9%) | 2 (11%) |
| Respiratory failure | 5 (7%) | 3 (5%) | 2 (11%) |
| Therapy-related MDS/leukemia | 3 (4%) | 2 (4%) | 1 (5%) |
| Other second cancer | 6 (8%) | 5 (9%) | 1 (5%) |
| Hepatic VOD | 2 (3%) | 1 (2%) | 1 (5%) |
| GVHD (post–allogeneic HCT) | 2 (3%) | 2 (4%) | 0 (0%) |
| Unknown/other | 6 (8%) | 6 (11%) | 0 (0%) |
| Post transplant toxicities | |||
| Pneumonitis, N (%)† | 49 (14%) | 23 (14%) | 26 (14%) |
| Therapy-related MDS/leukemia | 6 (2%) | 4 (3%) | 2 (1%) |
| Hepatic VOD | 3 (<1%) | 2 (1%) | 1 (<1%) |
| . | All patients (N = 342) . | AHCT in 2001-2010 (N = 159) . | AHCT in 2011-2020 (N = 183) . |
|---|---|---|---|
| All-cause mortality | |||
| Total number of deaths | 74 | 55 | 19 |
| Median follow-up after AHCT | 5.9 y | 11.6 y | 4.0 y |
| 4-y OS estimate | 83.8% | 79.0% | 89.1% |
| Causes of death | |||
| PD, N (%)∗ | 33 (45%) | 23 (42%) | 10 (53%) |
| Infection/sepsis | 10 (14%) | 8 (15%) | 2 (11%) |
| Cardiovascular disease | 7 (9%) | 5 (9%) | 2 (11%) |
| Respiratory failure | 5 (7%) | 3 (5%) | 2 (11%) |
| Therapy-related MDS/leukemia | 3 (4%) | 2 (4%) | 1 (5%) |
| Other second cancer | 6 (8%) | 5 (9%) | 1 (5%) |
| Hepatic VOD | 2 (3%) | 1 (2%) | 1 (5%) |
| GVHD (post–allogeneic HCT) | 2 (3%) | 2 (4%) | 0 (0%) |
| Unknown/other | 6 (8%) | 6 (11%) | 0 (0%) |
| Post transplant toxicities | |||
| Pneumonitis, N (%)† | 49 (14%) | 23 (14%) | 26 (14%) |
| Therapy-related MDS/leukemia | 6 (2%) | 4 (3%) | 2 (1%) |
| Hepatic VOD | 3 (<1%) | 2 (1%) | 1 (<1%) |